In This Article:
The Australian market saw a positive start to the week, with sectors like IT and Materials leading gains, buoyed by rising iron ore and gold prices. In this context, penny stocks—though an outdated term—remain a relevant investment area for those interested in smaller or newer companies. By focusing on stocks with strong financial health and growth potential, investors can uncover opportunities that might offer both stability and upside.
Top 10 Penny Stocks In Australia
Name | Share Price | Market Cap | Financial Health Rating |
CTI Logistics (ASX:CLX) | A$1.565 | A$122.09M | ★★★★☆☆ |
MotorCycle Holdings (ASX:MTO) | A$2.07 | A$152.78M | ★★★★★★ |
Accent Group (ASX:AX1) | A$1.815 | A$1.03B | ★★★★☆☆ |
EZZ Life Science Holdings (ASX:EZZ) | A$1.45 | A$68.4M | ★★★★★★ |
IVE Group (ASX:IGL) | A$2.42 | A$373.12M | ★★★★★☆ |
GTN (ASX:GTN) | A$0.62 | A$119.24M | ★★★★★★ |
Bisalloy Steel Group (ASX:BIS) | A$3.21 | A$152.31M | ★★★★★★ |
Regal Partners (ASX:RPL) | A$1.94 | A$652.16M | ★★★★★★ |
Southern Cross Electrical Engineering (ASX:SXE) | A$1.715 | A$453.22M | ★★★★★★ |
NRW Holdings (ASX:NWH) | A$2.39 | A$1.09B | ★★★★★☆ |
Click here to see the full list of 982 stocks from our ASX Penny Stocks screener.
Here's a peek at a few of the choices from the screener.
Clarity Pharmaceuticals
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Clarity Pharmaceuticals Ltd is a clinical stage radiopharmaceutical company focused on research and development of radiopharmaceutical products in Australia and the United States, with a market cap of A$560.76 million.
Operations: The company generates revenue primarily from its Radiopharmaceutical Development segment, amounting to A$10.78 million.
Market Cap: A$560.76M
Clarity Pharmaceuticals, with a market cap of A$560.76 million, is advancing its clinical stage radiopharmaceuticals, focusing on prostate cancer treatments. Recent milestones include the completion of the Dose Escalation Phase in the SECuRE trial and multiple Fast Track Designations from the FDA for its Cu-SAR-bisPSMA product. Despite being unprofitable and reporting a net loss of A$23.58 million for the half-year ending December 2024, Clarity maintains strong short-term assets (A$136.5 million) against liabilities and has no debt. The company's strategic focus on addressing unmet needs in prostate cancer could position it well within this niche market segment.
Deep Yellow
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Deep Yellow Limited is a uranium exploration company operating in Namibia and Australia, with a market cap of A$919.07 million.